A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3
A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3
复制标题
DOI：
10.1158/1078-0432.ccr-19-1513
复制
发表时间：
2020-04-01
影响因子：
11.5
通讯作者：
Park, Jong Sup
中科院分区：
文献类型：
--
作者：
Choi, Youn Jin;Hur, Soo Young;Park, Jong Sup
目的：确定治疗性DNA疫苗GX-188 E诱导宫颈上皮内瘤变（CIN）消退的疗效3.患者和方法：我们在人乳头瘤病毒（HPV）16/18型阳性的CIN 3患者中进行了一项GX-188 E的前瞻性、随机、多中心、开放标签、II期临床试验。主要终点是确定组织病理学消退，
Purpose: To determine the efficacy of the therapeutic DNA vaccine GX-188E for inducing regression of cervical intraepithelial neoplasia (CIN) 3.Patients and Methods: We conducted a prospective, randomized, multicenter, open-label, phase II clinical trial of GX-188E in CIN3 patients positive for human papillomavirus (HPV) type 16/18. The primary endpoint was to determine the histopathologic regression to